News|Articles|December 3, 2025
Unlocking Speed and Scalability in Biologics: GPEx® Lightning Executive Overview
Author(s)Catalent
Key Takeaways
Discover how Catalent’s GPEx® Lightning platform revolutionizes cell line development for complex biologics. This executive summary highlights how the platform enables rapid, high-titer expression of multispecific antibodies and other challenging proteins—accelerating timelines, improving production efficiency, and supporting commercial-scale manufacturing. Learn how tunable expression and digital control empower your team to overcome development bottlenecks and drive innovation in next-generation biologics.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Regulatory Uncertainty Surfaces as FDA Blames COVID Vaccines for 10 Child Deaths
2
New Draft Guidance Highlights FDA Push Toward Human-Relevant Safety Models
3
Implementing Automation and Flexible Design for Allogeneic Manufacturing
4
Rentschler–Coriolis Partnership Reflects Demand for Connected Biopharma Workflows
5
